Medical Condition

myelodysplastic syndrome

Total Trials

12

Recruiting Now

12

Trial Phases

Phase 2, Phase 1, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for myelodysplastic syndrome sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — myelodysplastic syndrome Clinical Trials

How many clinical trials are currently recruiting for myelodysplastic syndrome?

ClinicalMetric currently tracks 12 actively recruiting clinical trials for myelodysplastic syndrome, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 12. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for myelodysplastic syndrome?

myelodysplastic syndrome research spans Phase 1 (5 trials), Phase 2 (6 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a myelodysplastic syndrome clinical trial?

Eligibility criteria for myelodysplastic syndrome trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Top Sponsors

M.D. Anderson Cancer Center 3 trials

City of Hope Medical Center 2 trials

University of Wisconsin, Madison 1 trial

Haikou Affiliated Hospital of Central South University Xiangya School of Medicine 1 trial

Pharmacosmos A/S 1 trial

Recruiting Clinical Trials

NCT01624805 Phase 2

Recruiting

Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

View Trial →

NCT02115295 Phase 2

Recruiting

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

M.D. Anderson Cancer Center

View Trial →

NCT02508038 Phase 1

Recruiting

Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

University of Wisconsin, Madis...

View Trial →

NCT07763054

Recruiting

Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients

Haikou Affiliated Hospital of ...

View Trial →

NCT06543381 Phase 1

Recruiting

Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant

City of Hope Medical Center

View Trial →

NCT05693909 Phase 2

Recruiting

A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndromes

A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Edgewood Oncology Inc.

View Trial →

NCT07046078 Phase 2

Recruiting

Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer

Fred Hutchinson Cancer Center

View Trial →

NCT06059391 Phase 2

Recruiting

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

City of Hope Medical Center

View Trial →

NCT06773871

Recruiting

Feasibility and Safety of Exercise in Patients With Low-risk Myeloid Cancers and Precursor Conditions

Rigshospitalet, Denmark

View Trial →

NCT07573111 Phase 1

Recruiting

Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation

Laguna Biotherapeutics, Inc.

View Trial →

NCT05010122 Phase 1, Phase 2

Recruiting

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

View Trial →

Related Conditions

acute myeloid leukemia (8) acute lymphoblastic leukemia (3) de novo myelodysplastic syndrome (2) previously treated myelodysplastic syndrome (2) recurrent acute myeloid leukemia (2) refractory acute myeloid leukemia (2) hodgkin lymphoma (2) non hodgkin lymphoma (2) chronic lymphocytic leukemia (2) chronic myelomonocytic leukemia (2) aplastic anemia (1) acute biphenotypic leukemia (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology